IN-N01-OX2 development is being led by Dan Shochat, Ph.D., Consulting Vice President Development, an internationally recognized leader in the development of antibody products.
Dr. Shochat led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003.
At American Cyanamide Co. and in collaboration with Celltech, Dr. Shochat led the development of the first approved antibody-drug conjugate, Mylotarg®.
also invented the technology and single-vial formulation and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®.
With Dr. Shochat's
expert assistance, Intellect
has developed a detailed road-map for IN-N01-OX2 development to lead to the first clinical trials being initiated by the end of 2014.